{
    "clinical_study": {
        "@rank": "142809", 
        "acronym": "SNO-2", 
        "arm_group": [
            {
                "arm_group_label": "N6022", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of\n      N6022, and to obtain descriptive information on the effect of N6022 on biomarkers of CFTR\n      function and inflammation in adult cystic fibrosis subjects who are homozygous for the\n      F508del-CFTR mutation."
        }, 
        "brief_title": "Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized, placebo-controlled, multicenter, sequential\n      dose-escalation study which will occur in two parts. All selection criteria, assessments and\n      procedures described in this protocol will be applied to both parts. Up to 5 cohorts will be\n      studied with a total of 67 patients at approximately 18 clinical sites in the United States."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Homozygous for F508del-CFTR gene\n\n          -  Sweat chloride \u2265 60 mEq/L by quantitative pilocarpine iontophoresis\n\n          -  Body weight \u2265 40 kg\n\n          -  FEV1 \u2265 40% predicted\n\n          -  Oxygen saturation \u2265 90% breathing ambient air\n\n          -  Hematology and clinical chemistry of blood and urine results with no clinically\n             significant abnormalities that would interfere with the study assessments\n\n          -  Negative pregnancy test for women of child bearing potential\n\n          -  Sexually active subjects of child bearing potential willing to follow contraception\n             requirements\n\n        Exclusion Criteria:\n\n          -  Previous enrollment in another cohort for this study.\n\n          -  Any acute infection, including acute upper or lower respiratory infections and\n             pulmonary exacerbations that require treatment within 4 weeks of Study Day 1.\n\n          -  Any change in chronic therapies for CF lung disease within 4 weeks of Study Day 1.\n\n          -  Blood hemoglobin <10 g/dL at screening.\n\n          -  Serum albumin <2.5 g/dL at screening.\n\n          -  Abnormal liver function defined as \u2265 3 x upper limit of normal (ULN) in three or more\n             of the following: AST, ALT, GGT, ALP, total bilirubin at screening.\n\n          -  History of abnormal renal function (creatinine clearance < 50 mL/min using\n             Cockcroft-Gault equation) within a year at screening.\n\n          -  History, including the screening assessment, of ventricular tachycardia or\n             ventricular arrhythmias.\n\n          -  History, including the screening assessment, of prolonged QT and/or QTcF interval (>\n             450 msec).\n\n          -  History of solid organ or hematological transplantation.\n\n          -  Intranasal medication changes within 14 days prior to Study Day 1\n\n          -  Required Use of continuous (24 hr/d) or nocturnal supplemental oxygen.\n\n          -  Concomitant use of any inhibitors or inducers of CYP3A4."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "67", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746784", 
            "org_study_id": "N6022-1CF1-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "N6022", 
                "description": "Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose", 
                "intervention_name": "N6022", 
                "intervention_type": "Drug", 
                "other_name": "GSNORi"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "description": "Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cystic Fibrosis", 
            "F508del-CFTR", 
            "N6022", 
            "S-Nitrosoglutathione"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "Home page of Sponsor", 
            "url": "http://www.n30pharma.com/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anchorage", 
                        "country": "United States", 
                        "state": "Alaska", 
                        "zip": "99508"
                    }, 
                    "name": "Providence Alaska Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Stanford University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Children's Hospital Colorado"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80206"
                    }, 
                    "name": "National Jewish Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University of Iowa Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Boston Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Rainbow Babies and Children's Hospital - Case Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43205"
                    }, 
                    "name": "Nationwide Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15224"
                    }, 
                    "name": "Children's Hospital of Pittsburgh of UPMC"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)", 
        "other_outcome": [
            {
                "description": "Measured in plasma, induced sputum and stool.", 
                "measure": "Change in inflammatory biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 7 days"
            }, 
            {
                "measure": "Changes in cystic fibrosis respiratory symptom diary version 2 (CFRSD V2)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 7 days"
            }, 
            {
                "measure": "Patient global impression of change (PGIC)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 7 days"
            }
        ], 
        "overall_official": {
            "affiliation": "University of North Carolina, Chapel Hill", 
            "last_name": "Scott Donaldson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessments are based on numbers of subjects with abnormal clinical evaluations, abnormal laboratory assessments, and adverse events.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "Over 7 treatment days and 7 days of follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746784"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in percent predicted forced expiratory volume in 1 second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 7 days"
            }, 
            {
                "measure": "Change in biomarkers of CFTR function", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 7 days"
            }
        ], 
        "source": "N30 Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "N30 Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}